# Title

 Food and Drugs. PART 812â€”INVESTIGATIONAL DEVICE EXEMPTIONS


# ID

 CFR-2018-title21-vol8.Pt. 812


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                                                                                     |
|:------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['before', 'within', 'prior to', 'earlier than', 'later than', 'after', 'at least']                                                                                                                                                                                        |
| Duration    | ['30.0 day', '1.0 year', '2.0 year', '30 day', '6.0 month', '90.0 day', '5.0 day', '3.0 month']                                                                                                                                                                            |
| Condition   | ['until', 'unless and until', 'unless', 'not subject to', 'where', 'as soon as', 'subject to', 'when', 'provided that', 'if']                                                                                                                                              |
| Entities    | ['United States', 'Such', 'Docket Number', 'G609', 'Monitor', 'Rockville, MD', 'Emergency', 'Treatment', 'Termination', 'Scope', 'G112', 'Food', 'Acceptance', 'Import', 'Failure', 'Applicability', 'Address', 'Significant', 'Rm', 'Research', 'Beltsville, MD', 'Case'] |
| Date        | ['1980-07-16', '1981-01-19', '1976-05-28']                                                                                                                                                                                                                                 |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                             |
|:--------------|:------------------------------------------------------------------------------------------------------------------------------------|
| after         | &#167;&#8201;812.5; (ii) Obtains IRB approval of the investigation after presenting the reviewing IRB with a brief explanation      |
| before        | section, if the investigation was begun on or before July 16, 1980, and to be completed, and                                        |
| before        | section, if the investigation was begun on or before July 16, 1980, and to be completed, and                                        |
| before        | than a transitional device, in commercial distribution immediately before May 28, 1976, when used or investigated in                |
| after         | transitional device, introduced into commercial distribution on or after May 28, 1976, that FDA has determined to                   |
| before        | equivalent to a device in commercial distribution immediately before May 28, 1976, and that is used or                              |
| after         | the requirements of part 312 until 90 days after  that date.                                                                        |
| after         | To continue the investigation  after that date, a sponsor shall comply with paragraph                                               |
| within        | (b) A custom device means a device  within the meaning of section 520(b) of the Federal                                             |
| before        | of IRB or FDA approval, of an investigation before  completion.                                                                     |
| before        | be a new drug or an antibiotic drug before  May 28, 1976.                                                                           |
| after         | Promote or test market an investigational device, until after  FDA has approved the device for commercial distribution.             |
| after         | FDA shall provide a written determination 30 days  after  FDA receives the IDE or earlier.                                          |
| before        | favorable opinion) by an independent ethics committee (IEC) before initiating an investigation, continuing review of an ongoing     |
| before        | favorable opinion) by an independent ethics committee (IEC) before initiating an investigation, continuing review of an ongoing     |
| before        | situations when the IEC reviewing the investigation finds, before initiation of the investigation, that informed consent is         |
| within        | the data and information constitute valid scientific evidence within the meaning of &#167;&#8201;860.7 of this chapter; (7)         |
| at least      | A waiver request is required to contain  at least one of the following: (i) An explanation why                                      |
| after         | in support of an IDE, for 2 years after the termination or completion of the IDE; and                                               |
| after         | in support of an IDE, for 2 years after the termination or completion of the IDE; and                                               |
| after         | investigation may not begin until: (1) Thirty days after FDA receives the application at the address in                             |
| within        | to respond to a request for additional information within  the time prescribed by FDA.                                              |
| before        | FDA will provide the opportunity for hearing  before withdrawal of approval, unless FDA determines in the                           |
| before        | FDA will provide the opportunity for hearing  before withdrawal of approval, unless FDA determines in the                           |
| prior to      | appropriate (see &#167;&#167;&#8201;56.110 and 56.111 of this chapter), prior to  implementing a change to an investigational plan. |
| within        | Such deviation shall be reported to FDA  within 5-working days after the sponsor learns of it                                       |
| after         | shall be reported to FDA within 5-working days after  the sponsor learns of it (see &#167;&#8201;812.150(a)(4)).                    |
| within        | (3) Changes effected with notice to FDA  within  5 days.                                                                            |
| within        | section, and the sponsor provides notice to FDA within  5-working days of making these changes.                                     |
| later than    | notice of the change to the IDE not later than  5-working days after making the change.                                             |
| after         | to the IDE not later than 5-working days after  making the change.                                                                  |
| prior to      | During the clinical trial or  prior to final action on the marketing application, it may                                            |
| before        | early in the device development process as possible, before general marketing begins, and to obtain additional data                 |
| after         | made available for treatment use under this section after  all clinical trials have been completed.                                 |
| prior to      | made available for treatment use under this section prior to  the completion of all clinical trials.                                |
| within        | is a reasonable likelihood that death will occur within a matter of months or in which premature                                    |
| before        | the available regimens that ordinarily should be tried before using the investigational device or an explanation of                 |
| before        | investigator will be added to the treatment IDE before the agreement is signed; and (x) If the                                      |
| after         | Treatment use may begin 30 days  after FDA receives the treatment IDE submission at the                                             |
| earlier than  | &#167;&#8201;812.19, unless FDA notifies the sponsor in writing earlier than the 30 days that the treatment use may                 |
| before        | the file is not available for public disclosure before approval of an application for premarket approval or                         |
| later than    | Termination shall occur not  later than 5 working days after the sponsor makes this                                                 |
| after         | shall occur not later than 5 working days after the sponsor makes this determination and not later                                  |
| later than    | Termination shall occur not  later than 5 working days after the sponsor makes this                                                 |
| after         | shall occur not later than 5 working days after the sponsor makes this determination and not later                                  |
| before        | and shall not allow any subject to participate before  obtaining IRB and FDA approval.                                              |
| after         | eligible to receive test articles under this part. after                                                                            |
| after         | (d) If the Commissioner determines,  after the unreliable data submitted by the investigator are                                    |
| before        | shall have an opportunity for a regulatory hearing before FDA under part 16 of this chapter on                                      |
| after         | (e) If the Commissioner determines,  after the unreliable data submitted by the investigator are                                    |
| prior to      | individual shall document that informed consent was obtained prior to  participation in the study.                                  |
| after         | investigation and for a period of 2 years after the latter of the following two dates: The                                          |
| later than    | a transfer shall be given to FDA not later than  10 working days after transfer occurs.                                             |
| after         | to FDA not later than 10 working days after  transfer occurs.                                                                       |
| later than    | as soon as possible, but in no event later than 10 working days after the investigator first learns                                 |
| after         | in no event later than 10 working days after  the investigator first learns of the effect.                                          |
| within        | An investigator shall report to the sponsor,  within 5 working days, a withdrawal of approval by                                    |
| later than    | as soon as possible, but in no event later than  5 working days after the emergency occurred.                                       |
| after         | in no event later than 5 working days after  the emergency occurred.                                                                |
| within        | use to the sponsor and the reviewing IRB within  5 working days after the use occurs.                                               |
| after         | and the reviewing IRB within 5 working days after  the use occurs.                                                                  |
| within        | An investigator shall,  within 3 months after termination or completion of the                                                      |
| after         | An investigator shall, within 3 months  after termination or completion of the investigation or the                                 |
| within        | and to all reviewing IRB's and participating investigators within 10 working days after the sponsor first receives                  |
| after         | IRB's and participating investigators within 10 working days after  the sponsor first receives notice of the effect.                |
| after         | There after the sponsor shall submit such additional reports concerning                                                             |
| within        | part of an investigation by a reviewing IRB within 5 working days after receipt of the withdrawal                                   |
| after         | by a reviewing IRB within 5 working days after  receipt of the withdrawal of approval.                                              |
| within        | approval of the investigation, and shall do so within 5 working days after receipt of notice of                                     |
| after         | and shall do so within 5 working days after  receipt of notice of the withdrawal of approval.                                       |
| after         | shall submit the first such list 6 months after  FDA approval.                                                                      |
| at least      | At regular intervals, and  at least yearly, a sponsor shall submit progress reports to                                              |
| within        | Such notice shall occur  within 30 working days after the request is made                                                           |
| after         | Such notice shall occur within 30 working days  after the request is made and shall state why                                       |
| within        | significant risk device, the sponsor shall notify FDA within 30 working days of the completion or termination                       |
| within        | significant risk device, the sponsor shall notify FDA within 30 working days of the completion or termination                       |
| after         | the IRB's and participating investigators within 6 months after  completion or termination.                                         |
| within        | submit a final report to all reviewing IRB's within  6 months after termination or completion.                                      |
| after         | report to all reviewing IRB's within 6 months after  termination or completion.                                                     |
| within        | use of a device without obtaining informed consent, within 5 working days of receipt of notice of                                   |
| within        | to FDA a report of the IRB's determination within 5 working days after the sponsor first learns                                     |
| after         | of the IRB's determination within 5 working days after  the sponsor first learns of the IRB's determination.                        |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|:-----------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 90.0 day   | A sponsor that, on July 16, 1980, has an effective investigational new drug application (IND) for an investigation of a device shall continue to comply with the requirements of part 312 until 90 days after that date.                                                                                                                                                                                                                                                                                                                               |
| 30.0 day   | (d) Implant means a device that is placed into a surgically or naturally formed cavity of the human body if it is intended to remain there for a period of 30 days or more.                                                                                                                                                                                                                                                                                                                                                                            |
| 30.0 day   | FDA shall provide a written determination 30 days after FDA receives the IDE or earlier.                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 2.0 year   | A sponsor or applicant must retain the records required by this section for a clinical investigation conducted outside the United States as follows:                                                                                                                                                                                                                                                                                                                                                                                                   |
|            |               (1) If the investigation is submitted in support of an IDE, for 2 years after the termination or completion of the IDE; and                                                                                                                                                                                                                                                                                                                                                                                                              |
|            |               (2) If the investigation is submitted in support of a premarket approval application, a notice of completion of a product development protocol, a humanitarian device exemption application, a premarket notification submission, or a request for De Novo classification, for 2 years after an agency decision on that submission or application.                                                                                                                                                                                       |
| 2.0 year   | A sponsor or applicant must retain the records required by this section for a clinical investigation conducted outside the United States as follows:                                                                                                                                                                                                                                                                                                                                                                                                   |
|            |               (1) If the investigation is submitted in support of an IDE, for 2 years after the termination or completion of the IDE; and                                                                                                                                                                                                                                                                                                                                                                                                              |
|            |               (2) If the investigation is submitted in support of a premarket approval application, a notice of completion of a product development protocol, a humanitarian device exemption application, a premarket notification submission, or a request for De Novo classification, for 2 years after an agency decision on that submission or application.                                                                                                                                                                                       |
| 30 day     | An investigation may not begin until:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|            |               (1) Thirty days after FDA receives the application at the address in &#167;&#8201;812.19 for the investigation of a device other than a banned device, unless FDA notifies the sponsor that the investigation may not begin; or                                                                                                                                                                                                                                                                                                          |
|            |               (2) FDA approves, by order, an IDE for the investigation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 5.0 day    | (3) Changes effected with notice to FDA within 5 days.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 30.0 day   | Treatment use may begin 30 days after FDA receives the treatment IDE submission at the address specified in &#167;&#8201;812.19, unless FDA notifies the sponsor in writing earlier than the 30 days that the treatment use may or may not begin.                                                                                                                                                                                                                                                                                                      |
| 30.0 day   | Treatment use may begin 30 days after FDA receives the treatment IDE submission at the address specified in &#167;&#8201;812.19, unless FDA notifies the sponsor in writing earlier than the 30 days that the treatment use may or may not begin.                                                                                                                                                                                                                                                                                                      |
| 1.0 year   | The sponsor shall obtain a commitment from the clinical investigator to promptly update this information if any relevant changes occur during the course of the investigation and for 1 year following completion of the study.                                                                                                                                                                                                                                                                                                                        |
| 1.0 year   | The investigator shall promptly update this information if any relevant changes occur during the course of the investigation and for 1 year following completion of the study.                                                                                                                                                                                                                                                                                                                                                                         |
| 2.0 year   | An investigator or sponsor shall maintain the records required by this subpart during the investigation and for a period of 2 years after the latter of the following two dates: The date on which the investigation is terminated or completed, or the date that the records are no longer required for purposes of supporting a premarket approval application, a notice of completion of a product development protocol, a humanitarian device exemption application, a premarket notification submission, or a request for De Novo classification. |
| 3.0 month  | An investigator shall, within 3 months after termination or completion of the investigation or the investigator's part of the investigation, submit a final report to the sponsor and the reviewing IRB.                                                                                                                                                                                                                                                                                                                                               |
| 6.0 month  | A sponsor shall submit to FDA, at 6-month intervals, a current list of the names and addresses of all investigators participating in the investigation.                                                                                                                                                                                                                                                                                                                                                                                                |
| 6.0 month  | The sponsor shall submit the first such list 6 months after FDA approval.                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| 6.0 month  | In the case of a significant risk device, the sponsor shall notify FDA within 30 working days of the completion or termination of the investigation and shall submit a final report to FDA and all reviewing the IRB's and participating investigators within 6 months after completion or termination.                                                                                                                                                                                                                                                |
| 6.0 month  | In the case of a device that is not a significant risk device, the sponsor shall submit a final report to all reviewing IRB's within 6 months after termination or completion.                                                                                                                                                                                                                                                                                                                                                                         |


## Condition

| Condition        | Context                                                                                                                                                       |
|:-----------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------|
| if               | of the act, registration, listing, and premarket not if ication under section 510, performance standards under section                                        |
| unless           | Regulations are to chapter I of title 21, unless  otherwise noted.                                                                                            |
| unless           | are considered to have approved applications for IDE's, unless FDA has notified a sponsor under &#167;&#8201;812.20(a) that                                   |
| if               | approved applications for IDE's, unless FDA has not if ied a sponsor under &#167;&#8201;812.20(a) that approval of                                            |
| unless           | are considered to have approved applications for IDE's, unless FDA has notified a sponsor under &#167;&#8201;812.20(a) that                                   |
| subject to       | An investigation of a device other than one subject to paragraph (e) of this section, if the investigation                                                    |
| if               | one subject to paragraph (e) of this section, if the investigation was begun on or before July                                                                |
| when             | in commercial distribution immediately before May 28, 1976, when used or investigated in accordance with the indications                                      |
| if               | (3) A diagnostic device,  if the sponsor complies with applicable requirements in &#167;&#8201;809.10(c)                                                      |
| if               | (3) A diagnostic device,  if the sponsor complies with applicable requirements in &#167;&#8201;809.10(c)                                                      |
| if               | undergoing consumer preference testing, testing of a mod if ication, or testing of a combination of two                                                       |
| unless           | (7) A custom device as defined in &#167;&#8201;812.3(b),  unless the device is being used to determine safety                                                 |
| subject to       | (e) Investigations  subject to  IND's.                                                                                                                        |
| until            | to comply with the requirements of part 312 until  90 days after that date.                                                                                   |
| if               | shall comply with paragraph (b)(1) of this section, if  the device is not a sign                                                                              |
| if               | or naturally formed cavity of the human body if it is intended to remain there for a                                                                          |
| when             | (j) Monitor,  when used as a noun, means an individual designated                                                                                             |
| when             | Monitor,  when used as a verb, means to oversee an                                                                                                            |
| when             | (k) Noninvasive,  when applied to a diagnostic device or procedure, means                                                                                     |
| subject to       | (r) Transitional device means a device  subject to section 520(l) of the act, that is, a                                                                      |
| if               | effect on health or safety or any l if e-threatening problem or death caused by, or associated                                                                |
| subject to       | defined in paragraph (f) of this section and subject to the requirements of part 56 of this chapter,                                                          |
| if               | (in accordance with &#167;&#8201;801.1), the quantity of contents, if  appropriate, and the following statement: &#8220;CAUTION&#8212;Investigational device. |
| until            | (a) Promote or test market an investigational device, until after FDA has approved the device for commercial                                                  |
| unless and until | Any requirement shall continue to apply  unless and until  FDA waives it.                                                                                     |
| subject to       | imports or offers for importation an investigational device subject to this part shall be the agent of the                                                    |
| subject to       | A person exporting an investigational device  subject to this part shall obtain FDA's prior approval, as                                                      |
| if               | Document Mail Center, 10903 New Hampshire Ave., Bldg. if                                                                                                      |
| if               | A sponsor shall submit an application to FDA if  the sponsor intends to use a sign                                                                            |
| if               | A sponsor shall submit an application to FDA if  the sponsor intends to use a sign                                                                            |
| until            | which FDA's approval of an application is required until  FDA has approved the application.                                                                   |
| if               | of this chapter, the sponsor shall prominently ident if y on the cover sheet that the investigation                                                           |
| subject to       | on the cover sheet that the investigation is subject to  the requirements in &#167;&#8201;50.24 of this chapter.                                              |
| if               | complete report of prior investigations of the device if  no IRB has reviewed them,                                                                           |
| if               | complete report of prior investigations of the device if  no IRB has reviewed them,                                                                           |
| if               | complete report of prior investigations of the device if  no IRB has reviewed them,                                                                           |
| where            | used for the manufacture, processing, packing, storage, and, where appropriate, installation of the device, in sufficient detail                              |
| until            | no investigators will be added to the investigation until  they have signed the agreement.                                                                    |
| if               | sale does not constitute commercialization of the device. if                                                                                                  |
| if               | of all published and unpublished adverse information, and, if requested by an IRB or FDA, copies of                                                           |
| if               | good laboratory practice regulations in part 58, or if any such study was not conducted in compliance                                                         |
| if               | good laboratory practice regulations in part 58, or if any such study was not conducted in compliance                                                         |
| if               | investigational device exemptions regulations in this part, or if any such investigation was not conducted in compliance                                      |
| not subject to   | in part 56 of this chapter, or was not subject to the regulations under &#167;&#8201;56.104 or &#167;&#8201;56.105, and the                                   |
| if               | investigational device exemptions regulations in this part, or if any such investigation was not conducted in compliance                                      |
| if               | support the IDE, the requirements under &#167;&#8201;812.28 apply. if                                                                                         |
| if               | IDE or a device marketing application or submission if the investigation is well-designed and well-conducted and the                                          |
| provided that    | following conditions are met: (1) A statement is provided that the investigation was conducted in accordance with good                                        |
| if               | the subject (or a subject's legally authorized representative, if the subject is unable to provide informed consent)                                          |
| when             | does not require informed consent in life-threatening situations when the IEC reviewing the investigation finds, before initiation                            |
| if               | an onsite inspection, or through other appropriate means, if  the agency deems it necessary.                                                                  |
| where            | to another section of the application or submission where the information is located: (1) The names of                                                        |
| where            | to another section of the application or submission where the information is located: (1) The names of                                                        |
| if               | must provide either the following information, as spec if ied in paragraph (a)(2) of this section, or                                                         |
| if               | supporting such statement, including records describing the qual if ications of IEC members, and make these records                                           |
| if               | (2) FDA may grant a waiver  if it finds that doing so would be in                                                                                             |
| if               | a humanitarian device exemption application, a premarket not if ication submission, or a request for De Novo                                                  |
| if               | a humanitarian device exemption application, a premarket not if ication submission, or a request for De Novo                                                  |
| if               | IDE or a device marketing application or submission if FDA believes that the data and results from                                                            |
| unless           | of a device other than a banned device, unless FDA notifies the sponsor that the investigation may                                                            |
| if               | may disapprove or withdraw approval of an application if FDA finds that: (1) There has been a                                                                 |
| where            | used for the manufacturing, processing, packaging, storage, and, where appropriate, installation of the device; or (iii) Monitoring                           |
| unless           | the opportunity for hearing before withdrawal of approval, unless FDA determines in the notice that continuation of                                           |
| when             | a supplemental application under &#167;&#8201;812.30(a), and IRB approval when appropriate (see &#167;&#167;&#8201;56.110 and 56.111 of this chapter),        |
| if               | supplemental application under paragraph (a)(1) of this section if the sponsor determines that these changes meet the                                         |
| if               | section may be made without prior FDA approval if the sponsor submits a notice of the change                                                                  |
| when             | to a clinical protocol are deemed to occur when a clinical investigator is notified by the sponsor                                                            |
| when             | to a clinical protocol are deemed to occur when a clinical investigator is notified by the sponsor                                                            |
| if               | Such notices shall be ident if ied as a &#8220;notice of IDE change.&#8221; (A)                                                                               |
| until            | a part of an investigation at a facility until the IRB has approved the investigation, FDA has                                                                |
| if               | investigators participating in the treatment IDE and cert if ication that no investigator will be added to                                                    |
| unless           | IDE submission at the address specified in &#167;&#8201;812.19, unless FDA notifies the sponsor in writing earlier than                                       |
| until            | semi-annual basis to all reviewing IRB's and FDA until  the filing of a marketing application.                                                                |
| unless           | will not disclose the existence of an IDE unless its existence has previously been publicly disclosed or                                                      |
| until            | existence has previously been publicly disclosed or acknowledged, until FDA approves an application for premarket approval of                                 |
| subject to       | an application for premarket approval of the device subject to the IDE; or a notice of completion of                                                          |
| if               | If a device is a banned device or if the existence of an IDE has been publicly                                                                                |
| if               | If a device is a banned device or if the existence of an IDE has been publicly                                                                                |
| if               | in paragraphs (b)(1) and (c) of this section. if                                                                                                              |
| until            | begin an investigation or part of an investigation until an IRB and FDA have both approved the                                                                |
| where            | the dates, location, extent, and type of experience. where                                                                                                    |
| if               | explanation of the circumstances that led to termination. if                                                                                                  |
| if               | the clinical investigator to promptly update this information if any relevant changes occur during the course of                                              |
| unless           | investigator to dispose of or return the device, unless this action would jeopardize the rights, safety, or                                                   |
| as soon as       | investigations or parts of investigations presenting that risk as soon as  possible.                                                                          |
| if               | If the device is not a sign if icant risk device, a sponsor may not resume                                                                                    |
| when             | sponsor also shall monitor such investigations to determine when an IRB determines that it cannot approve the                                                 |
| if               | (b) If no IRB exists or  if FDA finds that an IRB's review is inadequate,                                                                                     |
| if               | (b) If no IRB exists or  if FDA finds that an IRB's review is inadequate,                                                                                     |
| where            | device, it shall so notify the investigator and, where  appropriate, the sponsor.                                                                             |
| subject to       | not request the written informed consent of any subject to  participate, and shall not allow any                                                              |
| subject to       | not request the written informed consent of any subject to  participate, and shall not allow any                                                              |
| if               | The investigator shall promptly update this information  if any relevant changes occur during the course of                                                   |
| if               | option of the investigator, in an informal conference. if                                                                                                     |
| if               | information, including any explanation presented by the investigator, if the Commissioner determines that the investigator has repeatedly                     |
| subject to       | be ineligible to receive FDA-regulated test articles is subject to examination to determine whether the investigator has submitted                            |
| if               | to continue the investigation, the Commissioner will not if y the sponsor, who shall have an opportunity                                                      |
| if               | which the data were submitted cannot be just if ied, the Commissioner will proceed to rescind clearance                                                       |
| when             | of this section may be reinstated as eligible when the Commissioner determines that the investigator has presented                                            |
| subject to       | (iii) A record of the exposure of each  subject to the investigational device, including the date and time                                                    |
| subject to       | (4) For each investigation  subject to &#167;&#8201;812.2(b)(1) of a device other than a significant                                                          |
| where            | reasonable manner, to enter and inspect any establishment where  devices are held (including any establishment                                                |
| where            | reasonable manner, to enter and inspect any establishment where  devices are held (including any establishment                                                |
| where            | reasonable manner, to enter and inspect any establishment where  devices are held (including any establishment                                                |
| as soon as       | unanticipated adverse device effect occurring during an investigation as soon as possible, but in no event later than 10                                      |
| as soon as       | Such notice shall be given  as soon as possible, but in no event later than 5                                                                                 |
| if               | changes in or deviations from a plan, and if  these changes or deviations may affect the scient                                                               |


## Entities

| Entities       | Context                                                                                                                    |
|:---------------|:---------------------------------------------------------------------------------------------------------------------------|
| Food           | Food  and Drugs.                                                                                                           |
| Scope          | Scope .                                                                                                                    |
| Applicability  | Applicability .                                                                                                            |
| Monitor        | Monitor , when used as a verb, means to                                                                                    |
| United States  | Limited by Federal (or  United States ) law to investigational use.&#8221; The label or                                    |
| Import         | Import  and export requirements.                                                                                           |
| Address        | Address  for IDE correspondence.                                                                                           |
| Food           | for Devices and Radiological Health, send it to Food and Drug Administration, Center for Devices and Radiological          |
| G609           | G609 , Silver Spring, MD 20993-0002.                                                                                       |
| Research       | regulated by the Center for Biologics Evaluation and Research , send it to the Food and Drug                               |
| Research       | regulated by the Center for Biologics Evaluation and Research , send it to the Food and Drug                               |
| Rm             | 71,  Rm .                                                                                                                  |
| G112           | G112 , Silver Spring, MD 20993-0002.                                                                                       |
| Research       | regulated by the Center for Drug Evaluation and Research , send it to Central Document Control Room,                       |
| Research       | regulated by the Center for Drug Evaluation and Research , send it to Central Document Control Room,                       |
| Beltsville, MD | Research, Food and Drug Administration, 5901-B Ammendale Rd., Beltsville, MD  20705-1266.                                  |
| Research       | Radiological Health, the Center for Biologics Evaluation and Research , or the Center for Drug Evaluation and              |
| Research       | Radiological Health, the Center for Biologics Evaluation and Research , or the Center for Drug Evaluation and              |
| Failure        | Failure or inability to comply with this requirement does                                                                  |
| United States  | If data from clinical investigations conducted in the United States are provided, a statement that each investigation was  |
| Failure        | Failure or inability to comply with these requirements does                                                                |
| United States  | If data from clinical investigations conducted outside the United States are provided to support the IDE, the requirements |
| Failure        | Failure or inability to comply with these requirements does                                                                |
| Acceptance     | Acceptance of data from clinical investigations conducted outside the                                                      |
| United States  | of data from clinical investigations conducted outside the United States .                                                 |
| United States  | of data from clinical investigations conducted outside the United States to support an IDE or a device marketing           |
| United States  | information on a clinical investigation conducted outside the United States to support an IDE or a device marketing        |
| United States  | data from a clinical investigation conducted outside the United States to support an IDE or a device marketing             |
| United States  | device used in the investigation conducted outside the United States is identical to the device that is the                |
| United States  | device used in the investigation conducted outside the United States is identical to the device that is the                |
| United States  | section for a clinical investigation conducted outside the United States as follows: (1) If the investigation is submitted |
| United States  | (e) Clinical investigations conducted outside of the  United States  that do not meet conditions.                          |
| United States  | For clinical investigations conducted outside the  United States that do not meet the conditions under paragraph           |
| Such           | Such deviation shall be reported to FDA within 5-working                                                                   |
| Treatment      | Treatment  use of an investigational device.                                                                               |
| Treatment      | Treatment use may begin 30 days after FDA receives                                                                         |
| Treatment      | Treatment use of an investigational device is conditioned upon                                                             |
| Docket Number  | IDE that was required to be filed in Docket Number 95S-0158 in the Division of Dockets Management (HFA-305),               |
| Rockville, MD  | 1061,  Rockville, MD 20852, for investigations involving an exception from informed                                        |
| Termination    | Termination shall occur not later than 5 working days                                                                      |
| Emergency      | Emergency  research under Â§â€‰50.24 of this chapter.                                                                         |
| Rockville, MD  | 1061,  Rockville, MD 20852, copies of the information that was disclosed,                                                  |
| Significant    | Significant  risk device determinations.                                                                                   |
| Research       | Radiological Health, the Center for Biologics Evaluation and Research , or the Center for Drug Evaluation and              |
| Case           | Case histories include the case report forms and supporting                                                                |


## Date

| Date       | Context                                                                                                                                                                                                                                                                                                                                                                                                               |
|:-----------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1980-07-16 | (2) An investigation of a device other than one subject to paragraph (e) of this section, if the investigation was begun on or before July 16, 1980, and to be completed, and is completed, on or before January 19, 1981.                                                                                                                                                                                            |
| 1981-01-19 | (2) An investigation of a device other than one subject to paragraph (e) of this section, if the investigation was begun on or before July 16, 1980, and to be completed, and is completed, on or before January 19, 1981.                                                                                                                                                                                            |
| 1976-05-28 | This part, with the exception of &#167;&#8201;812.119, does not apply to investigations of the following categories of devices:                                                                                                                                                                                                                                                                                       |
|            |               (1) A device, other than a transitional device, in commercial distribution immediately before May 28, 1976, when used or investigated in accordance with the indications in labeling in effect at that time.                                                                                                                                                                                            |
| 1976-05-28 | (2) A device, other than a transitional device, introduced into commercial distribution on or after May 28, 1976, that FDA has determined to be substantially equivalent to a device in commercial distribution immediately before May 28, 1976, and that is used or investigated in accordance with the indications in the labeling FDA reviewed under subpart E of part 807 in determining substantial equivalence. |
| 1976-05-28 | (2) A device, other than a transitional device, introduced into commercial distribution on or after May 28, 1976, that FDA has determined to be substantially equivalent to a device in commercial distribution immediately before May 28, 1976, and that is used or investigated in accordance with the indications in the labeling FDA reviewed under subpart E of part 807 in determining substantial equivalence. |
| 1980-07-16 | A sponsor that, on July 16, 1980, has an effective investigational new drug application (IND) for an investigation of a device shall continue to comply with the requirements of part 312 until 90 days after that date.                                                                                                                                                                                              |
| 1976-05-28 | (r) Transitional device means a device subject to section 520(l) of the act, that is, a device that FDA considered to be a new drug or an antibiotic drug before May 28, 1976.                                                                                                                                                                                                                                        |


